Financial statements Relyonart Biotech Investment Fund Inc.
Balance sheet of Relyonart Biotech Investment Fund Inc.
Company age:
Age:
12 y. 5 m. 19 d.
Share capital:
Share capital:
5 000 PLN
Balance sheet data of RELYONART BIOTECH INVESTMENT FUND INC.
|
Year
|
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
|---|---|---|---|---|---|---|---|
| Total assets | 2 002,13 | 2 092,90 | 2 113,10 | 1 663,00 | 3 087,40 | 3 508,58 | 2 646,98 |
| A. Fixed assets | 1 000,00 | 1 000,00 | 1 000,00 | 1 000,00 | 1 000,00 | 1 000,00 | 1 000,00 |
| B. Current assets | 1 002,13 | 1 092,90 | 1 113,10 | 663,00 | 2 087,40 | 2 508,58 | 1 646,98 |
| C. Share capital contributions (basic funds) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| D. Own shares (stocks) | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| Total liabilities | 2 002,13 | 2 092,90 | 2 113,10 | 1 663,00 | 3 087,40 | 3 508,58 | 2 646,98 |
| A. Equity | 353,93 | 764,50 | -863,50 | -188,20 | 621,20 | 1 902,38 | 672,78 |
| B. Liabilities and provisions for liabilities | 1 648,20 | 1 328,40 | 2 976,60 | 1 851,20 | 2 466,20 | 1 606,20 | 1 974,20 |
| I. Long-term liabilities | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 | 0,00 |
| II. Short-term liabilities | 1 648,20 | 1 328,40 | 2 976,60 | 1 851,20 | 2 466,20 | 1 606,20 | 1 974,20 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.
AD
AD